Eicosanoids and inflammatory bowel disease

Gastroenterology Clinics of North America

Volumn 25, Issue 2, 1996, Pages 317-332

  Yang, V W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ARACHIDONIC ACID; CORTICOSTEROID; ICOSANOID; LEUKOTRIENE; LIPOXYGENASE INHIBITOR; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; SALAZOSULFAPYRIDINE; ZILEUTON;

ARACHIDONIC ACID METABOLISM; CROHN DISEASE; ENTERITIS; HUMAN; INTESTINE MUCOSA; ORAL DRUG ADMINISTRATION; REVIEW; TOPICAL DRUG ADMINISTRATION; ULCERATIVE COLITIS;

EID: 0030008483     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8553(05)70249-1     Document Type: Article

References (78)

1. H. Allgayer W.F. Stenson A comparison of effects of sulfasalazine and its metabolites on the metabolism of endogenous vs. exogenous arachidonic acid Immunopharmacology 15 1988 39
2. J.P. Arm C.E. Horton B.W. Spur The effects of dietary supplementation with fish oil lipids on airway response to inhaled allergen in bronchial asthma Am Rev Respir Dis 139 1989 1395
3. D.G. Batt 5-Lipoxygenase inhibitors and their anti-inflammatory activities Prog Med Chem 29 1992 1
4. R.L. Bell J. Bouska P.R. Young The properties of A-69412: A small hydrophilic 5-lipoxygenase inhibitor Agents Actions 38 1993 178
5. R.L. Bell P.R. Young D. Albert The discovery and development of zileuton: An orally active 5-lipoxygenase inhibitor Int J Immunopharmacol 14 1992 505
6. G. Beyer K.E. Maier U. Klotz Enhanced synthesis of hydroxyeicosatetraenoic acids by colonic mucosa in chronic inflammatory bowel disease R.P. MacDermott Inflammatory Bowel Disease: Current Status and Future Approach 1988 Elsevier Science Publishers New York 291 296
7. 14C]-arachidonic acid by human colonic mucosa Gut 24 1983 1176
8. C. Collawn P. Rubin N. Perez Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis Am J Gastroenterol 87 1992 342
9. J.F. Cortese E.W. Spannhake W. Eisinger The 5-lipoxygenase pathway in cultured human intestinal epithelial cells Prostaglandins 49 1995 155
10. P.A. Craven F.R. DeRubertis Profiles of eicosanoid production by superficial and proliferative colonic epithelial cells and sub-epithelial colonic tissue Prostaglandins 32 1986 387
11. M. Depre B. Friedman W. Tanaka Biochemical activity, pharmacokinetics, and tolerability of MK-886, a leukotriene biosynthesis inhibitor, in humans Clin Pharmacol Ther 53 1993 602
12. D.L. DeWitt Prostaglandin endoperoxide synthase: Regulation of enzyme expression Biochim Biophys Acta 1083 1991 121
13. D.L. DeWitt E.A. Meade W.L. Smith PGH synthase isoenzyme selectivity: The potential for safer nonsteroidal antiinflammatory drugs Am J Med 95 suppl 2A 1993 40S
14. 4 synthesis in the human intestinal cell (CaCo-2) Gut 33 1991 622
15. R.A.F. Dixon R.E. Diehl E. Opas Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis Nature 343 1990 282
16. M. Donowitz Arachidonic acid metabolites and their role in inflammatory bowel disease: An update requiring addition of a pathway Gastroenterology 88 1985 580
17. J.M. Drazen K.F. Austen Leukotrienes and airway responses Am Rev Respir Dis 136 1987 985
18. K.W. Dreyling U. Hoppe B.A. Peskar Leukotriene synthesis by human gastrointestinal tissues Biochim Biophys Acta 878 1986 184
19. G. Feuerstein J.M. Hallenbeck Leukotrienes in health and disease FASEB J 1 1987 186
20. 4 in inflammation Crit Rev Immunol 10 1990 1
21. A.W. Ford-Hutchinson Regulation of leukotriene biosynthesis Cancer Metastasis Rev 13 1994 257
22. 4, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes Nature 286 1980 264
23. A.W. Ford-Hutchinson M. Gresser R.N. Young 5-Lipoxygenase Annu Rev Biochem 63 1994 383
24. 4 receptor antagonist SC-41930 on colonic inflammation in rat, guinea pig and rabbit J Pharmacol Exp Ther 255 1990 572
25. B.A. Friedman E.H. Bel A. Buntinx Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses Am Rev Respir Dis 147 1993 839
26. J. Gillard A.W. Ford-Hutchinson C. Chan L-663,536 (MK-886), a novel, orally active leukotriene biosynthesis inhibitor Can J Physiol Pharmacol 67 1989 456
27. E.J. Goetzl W.C. Pickett The human PMN leukocyte chemotactic activity of complex hydroxy-eicosatetraenoic acids (HETEs) J Immunol 125 1980 1789
28. S.R. Gould A.R. Brash M.E. Conolly Studies of prostaglandins and sulphasalazine in ulcerative colitis Prostaglandins Med 6 1981 165
29. W.R. Henderson The role of leukotrienes in inflammation Ann Intern Med 121 1994 684
30. H.R. Herschman Regulation of prostaglandin synthase-1 and prostaglandin synthase-2 Cancer Metastasis Rev 13 1994 241
31. M.J. Holtzman Arachidonic acid metabolism: Implications of biological chemistry for lung function and disease Am Rev Respir Dis 143 1991 188
32. C. Huet C. Sahuquillo-Merino E. Coudrier Absorptive and mucus-secreting subclones isolated from a multipotent intestinal cell line (HT-29) provide new models for cell polarity and terminal differentiation J Cell Biol 105 1987 345
33. N. Komatsu K. Natsui N. Ueda Immunohistochemical study on arachidonate 5-lipoxygenase in porcine leukocytes and other tissues J Histochem Cytochem 39 1991 655
34. D.A. Kujubu B.S. Fletcher B.C. Varnum TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/ cyclooxygenase homologue J Biol Chem 266 1991 12866
35. D.A. Kujubu H.R. Herschman Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene J Biol Chem 267 1992 7991
36. D.A. Kujubu S.T. Reddy B.S. Fletcher Expression of the protein product of the prostaglandin synthase-2/TIS10 gene in mitogen-stimulated Swiss 3T3 cells J Biol Chem 268 1993 5425
37. K. Lauritsen L.S. Laursen K. Bukhave In vivo effects of orally administered prednisolone on prostaglandin and leucotriene production in ulcerative colitis Gut 28 1987 1095
38. K. Lauritsen L.S. Laursen K. Bukhave Longterm olsalazine treatment: Pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis Gut 29 1988 974
39. L.S. Laursen J. Naesdal K. Bukhave Selective 5-lipoxygenase inhibition in ulcerative colitis Lancet 335 1992 683
40. R.A. Lewis K.F. Austen R.J. Soberman Leukotrienes and other products of the 5-lipoxygenase pathway: Biochemistry and relation to pathobiology in human diseases N Engl J Med 323 1990 645
41. 4 Dig Dis Sci 32 1987 1380
42. J.A. Mancini M. Abramovitz M.E. Cox 5-Lipoxygenase-activating protein is an arachidonate binding protein FEBS Lett 318 1993 277
43. J.L. Masferrer K. Seibert B. Zweifel Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme J Biol Chem 89 1992 3917
44. D.K. Miller J.W. Gillard P.J. Vickers Identification and isolation of a membrane protein necessary for leukotriene production Nature 343 1990 278
45. M.W. Musch R.J. Miller M. Field Stimulation of colonic secretion by lipoxygenase metabolites of arachidonic acid Science 217 1982 1255
46. J.H. Musser A.F. Kreft 5-Lipoxygenase: Properties, pharmacology, and the quinolinyl (bridged)aryl class of inhibitors J Med Chem 35 1992 2501
47. 4 antagonist, SR 2640, in ulcerative colitis: An open clinical study Prostaglandins Leukotrienes Essent Fatty Acids 42 1991 181
48. O.H. Nielsen K. Bukhave J. Elmgreen Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid Dig Dis Sci 6 1987 577
49. B.M. Peskar K.W. Dreyling B.A. Peskar Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: Inhibition by sulfasalazine and 5-aminosalicylic acid Agents Actions 18 1986 381
50. D.K. Podolsky Inflammatory bowel disease (first of two parts) N Engl J Med 325 1991 928
51. D.K. Podolsky Inflammatory bowel disease (second of two parts) N Engl J Med 325 1991 1008
52. P. Prasit M. Belley M. Blouin A new class of leukotriene biosynthesis inhibitor: The development of MK-0591 J Lipid Mediat 6 1993 239
53. D. Rachmilewitz P.L. Simon L.W. Schwartz Inflammatory mediators of experimental colitis in rats Gastroenterology 97 1989 326
54. L.C. Racusen H.J. Binder Effects of prostaglandin on ion transport across isolated colonic mucosa Dig Dis Sci 25 1980 900
55. J. Rask-Madsen Eicosanoids and their role in the pathogenesis of diarrhoeal diseases Clin Gastroenterol 15 1986 545
56. J. Rask-Madsen The role of eicosanoids in the gastrointestinal tract Scand J Gastroenterol 127 suppl 1987 7
57. C.A. Rouzer A.W. Ford-Hutchinson H.E. Morton MK-886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes J Biol Chem 265 1990 1436
58. C.A. Rouzer S. Kargman Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187 J Biol Chem 263 1988 10980
59. C.A. Rouzer B. Samuelsson On the nature of the 5-lipoxygenase reaction in human leukocytes: Enzyme purification and requirement for multiple stimulatory factors Proc Natl Acad Sci USA 82 1985 6040
60. B. Samuelsson Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation Science 220 1983 568
61. B. Samuelsson S. Dahlen J.A. Lindgren Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects Science 237 1987 1171
62. 4 and phosphatidic acid are calcium ionophores: Studies employing arsenazo III in liposomes J Biol Chem 257 1982 4746
63. P. Sharon M. Ligumsky D. Rachmilewitz Role of prostaglandins in ulcerative colitis: Enhanced production during active disease and inhibition by sulfasalazine Gastroenterology 75 1978 638
64. P. Sharon W.F. Stenson Metabolism of arachidonic acid in acetic acid colitis in rats: Similarity to human inflammatory bowel disease Gastroenterology 88 1985 55
65. 4 by colonic mucosa in inflammatory bowel disease Gastroenterology 86 1984 453
66. E. Sigal The molecular biology of mammalian arachidonic acid metabolism Am J Physiol 260 1991 L13
67. 4 Prostaglandins 45 1993 85
68. W.L. Smith E.A. Meade D.L. DeWitt Pharmacology of prostaglandin endoperoxide synthase isozymes-1 and -2 Ann NY Acad Sci 714 1994 136
69. W.F. Stenson Role of eicosanoids as mediators of inflammation in inflammatory bowel disease Scand J Gastroenterol 172 suppl 1990 13
70. W.F. Stenson E.A. Lobos Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils J Clin Invest 69 1982 494
71. S.P.L. Travis D.P. Jewell Salicylates for ulcerative colitis—their mode of action Pharmacol Ther 63 1994 135
72. J.L. Wallace C.M. Keenan An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis Am J Physiol 258 1990 G527
73. J.L. Wallace W.K. MacNaughton G.P. Morris Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease Gastroenterology 96 1989 29
74. C.N. Williams Overview of 5-ASA in therapy of inflammatory bowel disease Can J Gastroenterol 8 1994 379
75. J.W. Woods J.F. Evans D. Ethier 5-Lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes J Exp Med 178 1993 1935
76. S. Yamamoto Mammalian lipoxygenases: Molecular structures and functions Biochim Biophys Acta 1128 1992 117
77. B. Zingarelli F. Squadrito P. Graziani Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats Agents Actions 39 1993 150
78. 4 in rabbit colitis: Relationship to inflammation Gastroenterology 92 1987 33